- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01144182
Veterans Affairs Lowering Readmission in Heart Failure (VALOR in HF)
VALOR (Veterans Affairs Lowering Readmissions) in Heart Failure Study
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Heart failure (HF) greatly increases mortality and lowers quality of life (QOL). HF is the most common indication for readmission in older adults and the most frequent reason for 30-day readmission. Medications and restriction of dietary sodium constitute crucial therapy to lower HF recurrence. However, adherence to medications and dietary recommendations is low in HF patients. Nonadherence is often due to an interaction among the environment, the patient and providers. In the VALOR in Heart Failure Study, we will assess a novel quality improvement program (QIP) to improve HF care using a pretest-posttest design. This interdisciplinary theory-based prospective experimental study will target improving HF treatment using patient-based behavioral and checklist intervention, as well as provider and system-targeted checklists and treatment defaults (posttest or intervention phase); this will be compared to current best practice (CBP) evaluated in the pretest (pretest or pre-intervention) phase. It is hypothesized that the QIP, which intervenes on patient, provider and system levels, will improve QOL and lower HF recurrence compared to CBP.
The primary specific aims are 1) To test the effect of QIP on HF-specific quality of life compared to the CBP group, and 2) To evaluate the impact of QIP group on general quality of life compared to the CBP group.
Secondary specific aims are to:
1) assess the effect of QIP on medication adherence at 3 months, 2) examine the effect of QIP on diet adherence at 3 months, and 3) evaluate the effect of QIP on satisfaction, and 4) assess the effect of QIP on intervention acceptability. We will also examine the impact of QIP at 3 months on keeping routine outpatient visits, health-care utilization, exercise capacity, weight, perceived stress, depression, cardiovascular events and deaths.
Exploratory aim is to examine the effect of the QIP on 30 day post-discharge HF readmission rates compared to CBP.
We have enrolled 136 veterans being discharged from the hospital with a diagnosis of HF. Patients enrolled in the pretest phase will receive the HF management based on current best practice (CBP). Patients enrolled in the posttest phase receive the comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients. Data, including quality of life (QOL), medication adherence, and dietary adherence, will be collected from patients at baseline (prior to hospital discharge) and 3 months. Hospital readmissions, emergency room visits, and healthcare utilization will be tracked for 6 months. If, as expected, there are no differences in demographic or other confounders (EF, comorbidities, etc), the pretest and posttest groups will be compared by the Fisher's Exact test for discrete outcomes (30-day readmissions or ER visits). We will use the Student's ttest (two-tailed) for normally distributed outcomes and the Wilcoxon rank-sum test for categorical variables and continuous variables not normally distributed.
This study will inform and enhance quality improvement efforts in heart failure care in VA New York Harbor and elsewhere. It will also provide data for a rigorous effectiveness trial to test this promising intervention that could reduce HF recurrence and improve QOL in HF. If this promising theory-driven approach can work in a clinical setting where improvements in HF care are so urgent, it will be an important scientific contribution.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10010
- VA New York Harbor Health Care System
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- All patients admitted with either systolic or diastolic HF will be identified through ongoing daily prospective manual search of admission records in VA NYHHS
- Men and women ( 21 years) being discharged after a HF admission will be eligible
- They must have an available phone
Exclusion Criteria:
- Patients with poor short-term survival (< 3 months)
- recent major surgery (< 1 month)
- planned discharge to a long-term-care facility
- severe dementia or other serious psychiatric illness
- temporarily in the area
- those unable to provide consent, refusal to participate
- logistic or discretionary reasons (including participation in another study) will be excluded
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Sin intervención: Current Best Practice (CBP)
CBP received no intervention and only current best practices for inpatient HF care.
|
|
Comparador activo: Quality improvement program (QIP)
Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels.
The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking.
Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
|
Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels.
The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking.
Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
General Quality of Life From the Standardized Physical Component Score
Periodo de tiempo: 3 months after discharge
|
Assesses General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Heart Failure Specific Quality of Life
Periodo de tiempo: 3 months after discharge
|
Measured by Minnesota Living with Heart Failure Questionnaire.
Scores range from 0-105, with higher scores indicating poorer QOL.
|
3 months after discharge
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Standardized Mental Component Score
Periodo de tiempo: 3 months after discharge
|
Assesses General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Physical Functioning
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Role Physical
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Pain Index
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
General Health
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Vitality
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Social Functioning
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Role Emotional
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Mental Health
Periodo de tiempo: 3 months after discharge
|
Subscale of General Quality of Life from VR-36, with scores ranging from 0 to 100 and higher score indicating better quality of life
|
3 months after discharge
|
Physical Subscale of Heart Failure Specific Quality of Life
Periodo de tiempo: 3 months after discharge
|
Subscale of the Minnesota Living with Heart Failure Questionnaire (HF-specific quality of life measure).
Scores range from 0-40, with higher scores indicating poorer QOL.
|
3 months after discharge
|
Emotional Subscale of Heart Failure Specific Quality of Life
Periodo de tiempo: 3 months after discharge
|
Subscale of the Minnesota Living with Heart Failure Questionnaire (HF-specific quality of life measure).
Scores range from 0-25, with higher scores indicating poorer QOL.
|
3 months after discharge
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sundar Natarajan, MD MSc, VA New York Harbor Health Care System
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- RRP 09-412
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Insuficiencia cardiaca
-
Region SkaneInscripción por invitaciónInsuficiencia cardíaca New York Heart Association (NYHA) Clase II | Insuficiencia cardíaca New York Heart Association (NYHA) Clase IIISuecia
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... y otros colaboradoresAún no reclutandoInsuficiencia Cardíaca Sistólica | Insuficiencia cardíaca con fracción de eyección reducida | Insuficiencia cardíaca Clase IV de la New York Heart Association | Insuficiencia cardíaca Clase III de la New York Heart AssociationPolonia
-
Novartis PharmaceuticalsTerminadoPacientes que completaron con éxito el período de tratamiento de 12 meses del estudio principal (receptores de Novo Heart) que estaban interesados en recibir tratamiento con EC-MPS
-
University of WashingtonAmerican Heart AssociationTerminadoInsuficiencia cardíaca, congestiva | Alteración mitocondrial | Insuficiencia cardíaca Clase IV de la New York Heart AssociationEstados Unidos